Journal of Thoracic Oncology最新文献

{"title":"PP01.16 Ixazomib Overcomes Platinum Resistance and Induces Autophagy-Mediated Cell Death in Lung Adenocarcinoma","authors":"Muthamil Iniyan Appadurai , Zahraa Wajih Alsafwani , Sanjib Chaudhary , Ashu Shah , Pranay Somavarapu , Sriman N. Dooshety , Ben S. Kubicek , Surinder K. Batra , Imayavaramban Lakshmanan , Apar Kishor Ganti","doi":"10.1016/j.jtho.2025.03.023","DOIUrl":"10.1016/j.jtho.2025.03.023","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 4","pages":"Page S9"},"PeriodicalIF":21.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143759455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma-First Testing in Advanced Lung Cancer: Evidence and Implications","authors":"Kaushal Parikh M.B.B.S. , Ayesha Hashmi M.B.B.S. , Pradeep S. Chauhan PhD , Aadel A. Chaudhuri MD, PhD","doi":"10.1016/j.jtho.2025.01.014","DOIUrl":"10.1016/j.jtho.2025.01.014","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 4","pages":"Pages 411-414"},"PeriodicalIF":21.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143785088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Response to the Letter to the Editor: “Equipoise Is No Longer a Major Consideration in the Ethical Evaluation of Phase 3 Randomized Controlled Trials Involving Precision Oncology Approaches in NSCLC”","authors":"Jennifer W. Carlisle MD, Rebecca D. Pentz PhD, Suresh S. Ramalingam MD","doi":"10.1016/j.jtho.2025.01.025","DOIUrl":"10.1016/j.jtho.2025.01.025","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 4","pages":"Page e53"},"PeriodicalIF":21.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143785080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Response to the Letter to the Editor: “Linear Versus Non-Linear: Debunking Critiques on PCA Use in Molecular Subgrouping of Pulmonary Carcinoids”","authors":"Daphne J.G. Leunissen MSc, Laura Moonen PhD, Nicolas Alcala PhD, Ernst-Jan M. Speel PhD, Jules L. Derks MD, PhD","doi":"10.1016/j.jtho.2025.01.012","DOIUrl":"10.1016/j.jtho.2025.01.012","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 4","pages":"Pages e55-e56"},"PeriodicalIF":21.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143785172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PP01.13 Temporal Immune Evolution in a Murine EML4-ALK NSCLC Model: Genomic, Proteomic, and Drug Co-Culture Characterization","authors":"Marisa E. Aikins , Abdullah Saeed , Derek Nancarrow , Sydney Malawer , Tejas Thiyagarajan , Andrew Yu , Sofia E. Merajver , Kiran Lagisetty","doi":"10.1016/j.jtho.2025.03.020","DOIUrl":"10.1016/j.jtho.2025.03.020","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 4","pages":"Pages S7-S8"},"PeriodicalIF":21.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143759394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PP01.03 Characterization of Mutated KRAS Genotype and Clinical Outcomes in Patients With Advanced NSCLC Treated With Mecbotamab Vedotin, a CAB-AXL-ADC","authors":"Julia Rotow , Grace K. Dy , Edwin Yau , Elaine Shum , Mariam Alexander , Karen L. Reckamp , Roland Leung , Dariusz M. Kowalski , Jose Fuentes Pradera , Jon Zugazagoitia Fraile , Kyechin Chen , Kartik Aysola , D. Ross Camidge","doi":"10.1016/j.jtho.2025.03.011","DOIUrl":"10.1016/j.jtho.2025.03.011","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 4","pages":"Pages S3-S4"},"PeriodicalIF":21.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143759489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PP01.08 Pilot Study to Evaluate the Potential of the Tumor-Educated Platelets (TEP) as the Tool to Detect Minimal Residual Disease and Drug Resistance","authors":"Shuta Ohara , Kenichi Suda , Kazuko Sakai , Junko Tanaka , Takamichi Muramatsu , Chihiro Uematsu , Yasuhiro Tsutani , Kazuto Nishio , Tetsuya Mitsudomi","doi":"10.1016/j.jtho.2025.03.016","DOIUrl":"10.1016/j.jtho.2025.03.016","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 4","pages":"Page S6"},"PeriodicalIF":21.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143759521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Final Overall Survival and Long-Term Safety of Lorlatinib in Patients With ALK-Positive NSCLC From the Pivotal Phase 2 Study: A Brief Report","authors":"Sai-Hong Ignatius Ou MD, PhD ,&nbsp;Benjamin J. Solomon M.B.B.S., PhD ,&nbsp;Benjamin Besse MD, PhD ,&nbsp;Alessandra Bearz MD ,&nbsp;Chia-Chi Lin MD, PhD ,&nbsp;Rita Chiari MD, PhD ,&nbsp;D. Ross Camidge MD, PhD ,&nbsp;Jessica J. Lin MD ,&nbsp;Antonello Abbattista BSc ,&nbsp;Francesca Toffalorio MD, PhD ,&nbsp;Ross A. Soo M.B.B.S., FRACP, PhD","doi":"10.1016/j.jtho.2024.11.021","DOIUrl":"10.1016/j.jtho.2024.11.021","url":null,"abstract":"<div><h3>Introduction</h3><div>Lorlatinib is a potent, brain-penetrant, third-generation inhibitor of anaplastic lymphoma kinase (ALK) and ROS1 tyrosine kinases with broad coverage of <em>ALK</em> resistance mutations. We present the overall survival (OS) and long-term safety of lorlatinib in patients with advanced <em>ALK</em>-positive NSCLC from the final analyses of the pivotal phase 2 study.</div></div><div><h3>Methods</h3><div>Adults with <em>ALK</em>-positive NSCLC, enrolled in expansion cohorts (EXPs) on the basis of prior therapy (EXP1-5), received lorlatinib 100 mg orally once daily in continuous 21-day cycles. The primary endpoint was the objective response rate; secondary endpoints included OS and safety.</div></div><div><h3>Results</h3><div>Thirty patients were enrolled in EXP1 (treatment naïve), 59 in EXP2-3A (disease progression after crizotinib ± chemotherapy), 28 in EXP3B (disease progression after one second-generation ALK tyrosine kinase inhibitor [TKI] ± chemotherapy), 111 in EXP4-5 (disease progression after ≥2 ALK TKIs ± chemotherapy), and 139 in EXP3B-5 (disease progression after ≥1 ALK TKI ± chemotherapy). Median OS was not reached (NR) (95% confidence interval [CI]: NR–NR) in EXP1, NR (95% CI: 51.5–NR) in EXP2-3A, 37.4 months (95% CI: 12.3–NR) in EXP3B, 19.2 months (95% CI: 15.4–30.2) in EXP4-5, and 20.7 months (95% CI: 16.1–30.3) in EXP3B-5. All-cause adverse events leading to dose reduction were reported in 77 patients (28%), temporary treatment discontinuation in 158 patients (57%), and permanent discontinuation in 35 patients (13%).</div></div><div><h3>Conclusions</h3><div>After a minimum follow-up of five years, final analyses from the global phase 2 study confirmed substantial activity, prolonged OS, and generally consistent safety findings with lorlatinib in treatment-naïve and previously treated patients with <em>ALK</em>-positive NSCLC. <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> NCT01970865</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 4","pages":"Pages 513-520"},"PeriodicalIF":21.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142710553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decoding the Clinical and Molecular Signatures of EGFR Common, Compound, and Uncommon Mutations in NSCLC: A Brief Report","authors":"Daniele Tavernari PhD ,&nbsp;Maxime Borgeaud MD ,&nbsp;Ximeng Liu PhD ,&nbsp;Kaushal Parikh MD ,&nbsp;Xiuning Le MD, PhD ,&nbsp;Giovanni Ciriello PhD ,&nbsp;Alfredo Addeo MD","doi":"10.1016/j.jtho.2024.12.012","DOIUrl":"10.1016/j.jtho.2024.12.012","url":null,"abstract":"<div><h3>Introduction</h3><div>EGFR mutations are key oncogenic drivers in lung adenocarcinoma (LUAD), predominantly affecting Asian, nonsmoking, and female populations. Although common mutations, such as exon 19 deletions and L858R, respond well to tyrosine kinase inhibitors (TKIs), uncommon EGFR mutations and compound variants exhibit variable treatment responses. This study aims to compare clinical characteristics and molecular profiles of patients with common, uncommon, and compound EGFR mutations, assessing their implications for therapy outcomes.</div></div><div><h3>Methods</h3><div>We analyzed a multi-cohort genomic dataset of 19,163 patients with LUAD (5,212 with EGFR mutations), categorizing mutations into common, uncommon, and compound classes. Patient demographics, mutational signatures, and tumor microenvironment factors were assessed, with particular attention to smoking status and concomitant alterations in KRAS and TP53. Treatment outcomes were analyzed by time under treatment as a surrogate measure of TKI efficacy.</div></div><div><h3>Results</h3><div>Uncommon EGFR mutations, comprising 8.9% of EGFR-altered cases, were significantly more frequent among smokers and associated with tobacco-related mutational signatures. Compared with common EGFR-mutant cases, tumors harboring uncommon EGFR mutations reported higher rates of EGFR amplifications, KRAS, and TP53 mutations. Uncommon mutations also exhibited higher tumor mutational burden and distinct transcriptional profiles linked to cell cycle activity. Median time on treatment with TKIs was notably shorter in patients with uncommon mutations (4.1 mo) than those with common and compound mutations (10.9 mo and 12.4 mo, respectively).</div></div><div><h3>Conclusions</h3><div>This study underscores the clinical and molecular heterogeneity of EGFR mutation classes in LUAD, highlighting the unique profile of uncommon mutations, particularly their association with smoking and co-mutations in KRAS and TP53. Comprehensive molecular testing, including next-generation sequencing, is crucial to identify these uncommon mutations and inform therapeutic decisions. Further investigation into the role of immunotherapy in patients with uncommon EGFR mutations is warranted given the tobacco-related molecular signatures and high tumor mutational burden associated with this subgroup.</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 4","pages":"Pages 500-506"},"PeriodicalIF":21.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142854673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"OA07.01 KRAS Pharmacological Blockade Elicits Tumoral Homologous Recombination Deficiency Exploitable With PARP Inhibitors","authors":"Connor Welch ,&nbsp;Gabriela Novoa ,&nbsp;Alba Santos ,&nbsp;Carlos Vasquez ,&nbsp;Alejandra Lagos ,&nbsp;Iker Feliu ,&nbsp;Irati Macaya ,&nbsp;Nerea Bakartxo ,&nbsp;Rosario Prados-Carvajal ,&nbsp;Alberto Sogari ,&nbsp;Pablo Huertas ,&nbsp;Alfonso Calvo ,&nbsp;Elizabeth Guruceaga ,&nbsp;Luis Paz-Ares ,&nbsp;Alberto Bardelli ,&nbsp;Mariangela Russo ,&nbsp;Irene Ferrer ,&nbsp;Silve Vicent","doi":"10.1016/j.jtho.2025.03.008","DOIUrl":"10.1016/j.jtho.2025.03.008","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 4","pages":"Page S2"},"PeriodicalIF":21.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143759341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}